113 related articles for article (PubMed ID: 15948027)
1. Development of a transgenic mouse model immune tolerant for human interferon Beta.
Hermeling S; Jiskoot W; Crommelin D; Bornaes C; Schellekens H
Pharm Res; 2005 Jun; 22(6):847-51. PubMed ID: 15948027
[TBL] [Abstract][Full Text] [Related]
2. Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta.
van Beers MM; Sauerborn M; Gilli F; Hermeling S; Brinks V; Schellekens H; Jiskoot W
J Immunol Methods; 2010 Jan; 352(1-2):32-7. PubMed ID: 19857496
[TBL] [Abstract][Full Text] [Related]
3. Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice.
van Beers MM; Sauerborn M; Gilli F; Brinks V; Schellekens H; Jiskoot W
Pharm Res; 2010 Sep; 27(9):1812-24. PubMed ID: 20499141
[TBL] [Abstract][Full Text] [Related]
4. A modified immune tolerant mouse model to study the immunogenicity of recombinant human interferon beta.
Abdolvahab MH; Brinks V; Schellekens H
J Immunol Methods; 2014 Dec; 415():17-23. PubMed ID: 25450255
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of Recombinant Human Interferon Beta-1b in Immune-Tolerant Transgenic Mice Corresponds with the Biophysical Characteristics of Aggregates.
Abdolvahab MH; Fazeli A; Halim A; Sediq AS; Fazeli MR; Schellekens H
J Interferon Cytokine Res; 2016 Apr; 36(4):247-57. PubMed ID: 26835734
[TBL] [Abstract][Full Text] [Related]
6. An Albumin-Free Formulation for Escherichia coli-Derived Interferon Beta-1b with Decreased Immunogenicity in Immune Tolerant Mice.
Abdolvahab MH; Fazeli A; Radmalekshahi M; Nejadnik MR; Fazeli MR; Schellekens H
J Interferon Cytokine Res; 2016 Mar; 36(3):192-203. PubMed ID: 26824268
[TBL] [Abstract][Full Text] [Related]
7. Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice.
van Beers MM; Sauerborn M; Gilli F; Brinks V; Schellekens H; Jiskoot W
Pharm Res; 2011 Oct; 28(10):2393-402. PubMed ID: 21544687
[TBL] [Abstract][Full Text] [Related]
8. Development of ADA against recombinant human interferon beta in immune tolerant mice requires rapid recruitment of CD4⁺ T cells, induces formation of germinal centers but lacks susceptibility for (most) adjuvants.
Kijanka G; Sauerborn M; Boon L; Schellekens H; Brinks V
J Pharm Sci; 2015 Feb; 104(2):396-406. PubMed ID: 25219665
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene.
Van Beers MM; Gilli F; Schellekens H; Randolph TW; Jiskoot W
J Pharm Sci; 2012 Jan; 101(1):187-99. PubMed ID: 21918983
[TBL] [Abstract][Full Text] [Related]
10. Development of a bioassay for quantification of neutralising antibodies against human interferon-beta in mouse sera.
Gilli F; van Beers M; Marnetto F; Jiskoot W; Bertolotto A; Schellekens H
J Immunol Methods; 2008 Jul; 336(2):119-26. PubMed ID: 18558408
[TBL] [Abstract][Full Text] [Related]
11. Antibody response against Betaferon® in immune tolerant mice: involvement of marginal zone B-cells and CD4+ T-cells and apparent lack of immunological memory.
Sauerborn M; van Beers MM; Jiskoot W; Kijanka GM; Boon L; Schellekens H; Brinks V
J Clin Immunol; 2013 Jan; 33(1):255-63. PubMed ID: 22945588
[TBL] [Abstract][Full Text] [Related]
12. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation.
Hermeling S; Schellekens H; Maas C; Gebbink MF; Crommelin DJ; Jiskoot W
J Pharm Sci; 2006 May; 95(5):1084-96. PubMed ID: 16552750
[TBL] [Abstract][Full Text] [Related]
13. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b.
Hermeling S; Aranha L; Damen JM; Slijper M; Schellekens H; Crommelin DJ; Jiskoot W
Pharm Res; 2005 Dec; 22(12):1997-2006. PubMed ID: 16184451
[TBL] [Abstract][Full Text] [Related]
14. Interferon-β lipofection II. Mechanisms involved in cell death and bystander effect induced by cationic lipid-mediated interferon-β gene transfer to human tumor cells.
Villaverde MS; Gil-Cardeza ML; Glikin GC; Finocchiaro LM
Cancer Gene Ther; 2012 Jun; 19(6):420-30. PubMed ID: 22555508
[TBL] [Abstract][Full Text] [Related]
15. Development of a transgenic mouse model to study the immunogenicity of recombinant human insulin.
Torosantucci R; Brinks V; Kijanka G; Halim LA; Sauerborn M; Schellekens H; Jiskoot W
J Pharm Sci; 2014 May; 103(5):1367-74. PubMed ID: 24619587
[TBL] [Abstract][Full Text] [Related]
16. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model.
Rowse GJ; Tempero RM; VanLith ML; Hollingsworth MA; Gendler SJ
Cancer Res; 1998 Jan; 58(2):315-21. PubMed ID: 9443411
[TBL] [Abstract][Full Text] [Related]
17. Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics.
Bi V; Jawa V; Joubert MK; Kaliyaperumal A; Eakin C; Richmond K; Pan O; Sun J; Hokom M; Goletz TJ; Wypych J; Zhou L; Kerwin BA; Narhi LO; Arora T
J Pharm Sci; 2013 Oct; 102(10):3545-55. PubMed ID: 23925953
[TBL] [Abstract][Full Text] [Related]
18. Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice.
Li Q; Cao C; Chackerian B; Schiller J; Gordon M; Ugen KE; Morgan D
BMC Neurosci; 2004 Jun; 5():21. PubMed ID: 15186505
[TBL] [Abstract][Full Text] [Related]
19. lacZ transgenic rats tolerant for beta-galactosidase: recipients for gene transfer studies using lacZ as a reporter gene.
Ménoret S; Aubert D; Tesson L; Braudeau C; Pichard V; Ferry N; Anegon I
Hum Gene Ther; 2002 Jul; 13(11):1383-90. PubMed ID: 12162820
[TBL] [Abstract][Full Text] [Related]
20. Effect of treatment regimen on the immunogenicity of human interferon Beta in immune tolerant mice.
Kijanka G; Jiskoot W; Schellekens H; Brinks V
Pharm Res; 2013 Jun; 30(6):1553-60. PubMed ID: 23361590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
